aibioBioNexus advances VitaGuard rollout in Southeast Asia
Tickers BGLC
After a working visit to China, BioNexus says it is preparing the VitaGuard platform for ten licensed Southeast Asian markets.
Key facts
- Company
- BioNexus Gene Lab Corp (NASDAQ: BGLC)
- News type
- Company Updates
- Primary source
- BioNexus Gene Lab Corp 8-K (2026-07-28)
BioNexus Gene Lab Corp. (Nasdaq: BGLC) said on July 28, 2026 that it is making progress toward commercializing the VitaGuard molecular residual disease (MRD) platform in Southeast Asia. The announcement followed a working visit to facilities of the Tongshu Gene group in Shanghai and Changzhou, China. The visit was led by Dr. Muthu Meyyappan, Chief Commercial Officer of Fidelion Diagnostics Pte. Ltd. The company furnished the release in a Form 8-K filed the same day.
What VitaGuard is
VitaGuard is a tumor-naive, fixed-panel liquid biopsy platform that uses next-generation sequencing to look for circulating tumor DNA associated with MRD in solid tumors. The system combines blood stabilization, cell-free DNA extraction, targeted sequencing, bioinformatics and reporting that can track molecular changes over time. Unlike patient-specific tests that first require a panel designed from tumor tissue, VitaGuard uses a fixed panel intended to make repeat blood-based monitoring simpler to deploy.
According to Tongshu Gene, VitaGuard is currently used on a paid commercial basis at numerous hospitals across China.
The visit
The visit combined technical planning with meetings at selected Chinese hospitals where VitaGuard is in paid commercial use. Dr. Meyyappan and the Fidelion team visited selected sites and met physicians and laboratory personnel who use the platform. The release says their feedback was positive and gave the team a closer look at how VitaGuard fits into day-to-day workflows. It also says these visits were not a formal clinical evaluation.
The working sessions reviewed what will be needed to implement VitaGuard in Southeast Asia under the existing assignment and license agreements. The topics included laboratory workflows, documentation, reagents, system requirements, local implementation and commercial coordination. The teams also discussed routes to market, including territorial licensing, laboratory partnerships, pharmaceutical collaborations and other strategic relationships.
The license and the investment
In November 2025, Wuxi Tongshu Biotechnology Co., Limited, the contracting company within the Tongshu Gene group, assigned the VitaGuard intellectual property rights outside the People's Republic of China to Fidelion. In the ten Southeast Asian markets named in BioNexus's license, the company's exclusive rights cover the use, development, manufacture, marketing, distribution and sale of VitaGuard-based products and services. BioNexus may also pursue local regulatory approvals and other commercial relationships in those markets. With Fidelion's prior written consent, as the license requires, BioNexus may grant sublicenses.
The release says the ten licensed markets have a population of more than 680 million. BioNexus also owns approximately 15% of Fidelion. The company says the license and investment give it two paths to participate in VitaGuard's growth: directly through its Southeast Asian business and indirectly through Fidelion's licensing and partnerships elsewhere.
Cost and repeat testing
BioNexus has previously said it expects VitaGuard's cost per test to be under US$300, before local pricing, reimbursement and implementation considerations. The release says management believes that, if achieved, this could make repeat molecular monitoring more accessible in cost-sensitive healthcare systems.
Financial position
BioNexus's 10-K filed April 14, 2026 reports revenue of $7.4 million for 2025, compared with $9.5 million for 2024. Research and development expense was $50,670 in 2025 and $47,511 in 2024. The net loss was $3.0 million for 2025 and $1.6 million for 2024. Cash from operations was negative $1.8 million in 2025 and negative $2.1 million in 2024. Cash and cash equivalents were $2.9 million at year-end 2024.
The risks ahead
BioNexus has not yet deployed VitaGuard in Southeast Asia. The release lists transfer, localization, verification, validation and implementation as ongoing work, and says the target of initial deployment in select medical hubs during 2026 depends on finishing that work and on approvals. The cost per test under US$300 is a stated expectation, before local pricing and reimbursement. The visits were not a clinical evaluation. Fidelion has no definitive agreement for markets outside Southeast Asia. BioNexus reported falling revenue, a net loss and negative operating cash flow for 2025: revenue of $7.4 million against $9.5 million for 2024, a net loss of $3.0 million and cash from operations of negative $1.8 million.